The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Challenges in monitoring for cardiotoxicity when treating patients with CLL
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the issue of cardiac toxicity associated with BTK inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL), noting that while newer generations of these drugs show less toxicity than ibrutinib, all agents carry some risk. She highlights the challenge of assessing whether cardiac effects are drug-induced or due to patient comorbidities and emphasizes the importance of individualized risk-benefit decisions. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Newave, Loxo, Beigene, AstraZeneca, Abbvie, Janssen, Pharmacyclics; Research Funding: Schrodinger, Morphosys, Karyopharm, Janssen, Pharmacyclics.
